NT-proBNP independently predicted long-term all-cause mortality across all eGFR subgroups, with optimal cut-offs of >1837, >1413, and >6415 pg/mL for eGFR >60, 30-60, and <30 mL/min/1.73 m2.
Observational (n=716)
NT-proBNP on admission remains an independent predictor of long-term all-cause mortality in hospitalized heart failure patients regardless of renal function, though prognostic cut-off values are significantly higher in patients with severe renal dysfunction.
Background/Objectives: The coexistence of heart failure (HF) and chronic kidney disease (CKD) complicates management and worsens prognosis. NT-proBNP is a recognized biomarker for HF diagnosis and prognosis, yet its interpretation in CKD can be challenging due to confounding factors increasing its levels. This study aimed to evaluate the predictive value of NT-proBNP for all-cause long-term mortality in HF patients across various stages of renal dysfunction. Methods: Hospitalized HF patients were included in this observational, retrospective analysis. NT-proBNP levels and serum creatinine were measured on admission. The primary outcome was all-cause mortality. Patients were divided into three groups according to renal function estimated using the CKD-EPI formula: eGFR1 (>60 mL/min/1.73 m2), eGFR2 (30–60 mL/min/1.73 m2) and eGFR3 (1837 pg/mL in eGFR1 patients, >1413 pg/mL in eGFR2 and >6415 pg/mL in eGFR3. In multivariable Cox analysis, NT-proBNP was an independent predictor of all-cause long-term mortality in all eGFR groups. Conclusions: NT-proBNP on admission was an independent predictor of long-term all-cause mortality in hospitalized HF patients across all eGFR subgroups, with increasing cut-off levels in patients with renal dysfunction.
Breha et al. (Sat,) conducted a observational in Heart failure (n=716). NT-proBNP was evaluated on All-cause mortality. NT-proBNP independently predicted long-term all-cause mortality across all eGFR subgroups, with optimal cut-offs of >1837, >1413, and >6415 pg/mL for eGFR >60, 30-60, and <30 mL/min/1.73 m2.